成纤维细胞生长因子23作为ST段抬高型心肌梗死早期风险分层的新型生物标志物
前瞻性观察性研究纳入88例接受直接经皮冠状动脉介入治疗的ST段抬高型心肌梗死患者,于症状发作后2天检测成纤维细胞生长因子23(FGF-23)浓度,并用心脏磁共振评估左心室重构。发生左心室重构者FGF-23水平显著高于未发生者,校正心肌坏死、心肌应力和炎症标志物后关联仍显著,将FGF-23加入已有标志物可改善重构预测。
要点
- 发生左心室重构者FGF-23为152.6(102.5-241.3)相对单位/毫升,高于未发生者的75.8(58.6-105.4),p=0.002。
- 校正hs-cTnT、NT-proBNP和hs-CRP后,FGF-23与左心室重构的OR为14.1(95%CI 2.8至70.9),p=0.001。
- 将FGF-23加入hs-cTnT、NT-proBNP和hs-CRP后,净重分类改善为0.92(95%CI 0.44至1.41),p<0.001。
核心结论
- 循环FGF-23与再灌注后ST段抬高型心肌梗死后的左心室重构独立相关。
- 包含FGF-23的综合多标志物策略对左心室重构的预测具有增量预后价值。
研究设计与样本
- 前瞻性观察性研究,纳入88例接受直接经皮冠状动脉介入治疗的ST段抬高型心肌梗死连续患者。
- 于症状发作后2(IQR:2-2)天检测FGF-23浓度。
- 于梗死後2(IQR:1-3)天及4(IQR:4-5)个月行心脏磁共振评估左心室重构,定义为左心室舒张末期容积增加≥20%。
主要发现
- 发生左心室重构者11例(13%),其FGF-23水平为152.6(102.5-241.3)相对单位/毫升,高于未发生者的75.8(58.6-105.4)相对单位/毫升,p=0.002。
- 校正hs-cTnT、NT-proBNP和hs-CRP后,FGF-23与左心室重构的关联仍显著,OR为14.1(95%CI 2.8至70.9),p=0.001。
- 将FGF-23加入hs-cTnT、NT-proBNP和hs-CRP后,净重分类改善为0.92(95%CI 0.44至1.41),p<0.001。
- 将FGF-23加入hs-cTnT、NT-proBNP和hs-CRP后,综合判别改善为0.16(95%CI 0.08至0.24),p<0.001。
关键数值与推荐
- 左心室重构定义为左心室舒张末期容积增加≥20%。
- FGF-23与左心室重构的校正OR为14.1(95%CI 2.8至70.9),p=0.001。
- 净重分类改善为0.92(95%CI 0.44至1.41),p<0.001。
- 综合判别改善为0.16(95%CI 0.08至0.24),p<0.001。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Adverse left ventricular (LV) remodelling is the major determinant of heart failure and mortality in survivors of ST-elevation myocardial infarction (STEMI). The role of fibroblast growth factor 23 (FGF-23) for LV remodelling prediction after STEMI is unknown. We therefore aimed to investigate the relation between circulating FGF-23 and LV remodelling following revascularised STEMI. METHODS: In this prospective observational study, we included 88 consecutive patients with STEMI treated by primary percutaneous coronary intervention. FGF-23 concentrations were measured 2 (IQR: 2-2) days after symptom onset. Cardiac magnetic resonance was performed 2 (IQR: 1-3) days as well as 4 (IQR: 4-5) months after infarction to evaluate LV remodelling, defined as ≥20% increase in LV end-diastolic volume. RESULTS: Levels of FGF-23 were significantly higher in patients who developed LV remodelling (n=11, 13%) as compared with those without LV remodelling (152.6 (102.5-241.3) vs 75.8 (58.6-105.4) relative units per millilitre, p=0.002). The association between FGF-23 and LV remodelling remained significant (OR: 14.1, 95% CI 2.8 to 70.9; p=0.001) after adjustment for biomarkers reflecting myocardial necrosis (high-sensitivity cardiac troponin T (hs-cTnT)), myocardial stress (N-terminal pro B-type natriuretic peptide (NT-proBNP)) and inflammatory state (high-sensitivity C reactive protein (hs-CRP)). Moreover, a multimarker approach adding FGF-23 to the established LV remodelling-predictive biomarkers (hs-cTnT, NT-proBNP and hs-CRP) led to a net reclassification improvement of 0.92 (95% CI 0.44 to 1.41, p<0.001) and to an integrated discrimination improvement of 0.16 (95% CI 0.08 to 0.24, p<0.001). CONCLUSIONS: Circulating FGF-23 is independently associated with LV remodelling after reperfused STEMI. A comprehensive multimarker strategy that includes FGF-23 provides incremental prognostic value for prediction of LV remodelling.
引用
- Reindl M, Reinstadler SJ, Feistritzer HJ, et al. Fibroblast growth factor 23 as novel biomarker for early risk stratification after ST-elevation myocardial infarction. Heart. 2016. PMID: 27979879. doi:10.1136/heartjnl-2016-310520
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。